Introduction
One of the essential features of the blood-brain barrier (BBB) is the presence of complex intercellular tight junctions between adjacent endothelial cells, 1 which results in a very high transendothelial electrical resistance, estimated at ~1,800 Ω cm 2 , 2 and severely restricts paracellular passage of polar compounds when compared to vascular beds in other organs. 3 Impairment of the BBB is recognized as either a pathophysiologic consequence or a cause of multiple disease states affecting the CNS, including traumatic brain injury, ischemic stroke, brain tumors, and neuroinflammatory, infectious, or neurodegenerative brain disorders. [4] [5] [6] [7] [8] Measurement of passive BBB permeability is therefore one of the most frequently used parameters in experimental and clinical studies.
Diverse markers ranging from vital dyes, such as Evans Blue, 9 and sugars, like sucrose and inulin, 10 to proteins, such as radiolabeled albumin 10, 11 and horseradish peroxidase, 12 have been used in the BBB field in preclinical studies to determine the integrity of the barrier. For the quantification of subtle changes in paracellular permeability, no single ideal marker has emerged to date. 13 For example, as a hydrophilic small drug molecule, atenolol has been occasionally used to represent putative paracellular transport. [14] [15] [16] However, while atenolol is 99% charged at physiological pH, transcellular passage of the neutral form may account for a fraction of brain uptake measured in vivo. 17 In practical terms, a permeability marker should not have significant pharmacological effects, as it could alter physiological parameters. While not a drug itself, the disaccharide sucrose may be considered the most widely accepted standard for the precise measurement of paracellular BBB permeability. [18] [19] [20] [21] [22] This is because sucrose is uncharged, not subject to protein binding, metabolically stable after parenteral administration, falling into the molecular weight range of most small molecule drugs, and, to our knowledge, lacking measurable membrane transport by active or facilitative mechanisms in vertebrates. With respect to in vivo studies, a recent review 13 on BBB markers rated radiolabeled sucrose as the only small molecular weight agent providing quantitatively accurate data. However, at least one earlier literature report 23 indicated that radiolabeled sucrose, especially when used in typical fashion with counting of just the whole radioactivity in blood and tissue samples (i.e. without chromatographic separation), may give spurious data due to presence of minor lipophilic contaminants.
To potentially replace radiolabeled tracers and circumvent the non-specificity of total radioactivity measurement associated with the use of [ 14 C]sucrose, we recently introduced a highly specific and sensitive non-radioactive technique for measurement of BBB permeability, based on LC-MS/MS detection of [ 13 C]sucrose. 24 In the current study, we conducted a rigorous side-by side comparison of the two isotopically labeled sucrose analogs after intravenous bolus injection in rats.
Materials and Methods

Chemicals and Reagents
We purchased [UL- 13 C 12 ]sucrose (all the carbons in both glucose and fructose molecules are labeled with 13 analysis, plasma samples were diluted 100 times with water, and brain was homogenized in icecold water at a ratio of 1:9 to obtain brain homogenate. The brain homogenate and diluted plasma samples were analyzed by the LC-MS/MS method as described below.
Fractionation of Plasma and Brain [ 14 C]Sucrose after In Vivo Administration
After an overnight fast, rats (n = 3) were anesthetized with a ketamine: xylazine mixture (80:8 mg/kg) via intramuscular injection, and [ 14 C]sucrose was injected at a dose of 100 µCi/animal (~ 170 µg/kg) via penile vein. During anesthesia, the body temperature of rats was maintained at 37ᴼC. One h after the sucrose injection, a blood sample was collected from a femoral artery catheter and plasma was separated. Additionally, a catheter was placed in the left ventricle of the heart, and whole body perfusion was conducted with ice-cold saline at a rate of 25 mL/min for 5 min. Subsequently, the brain was collected and snap-frozen in cold (-80ᴼC) isopentane. The whole brain was homogenized in ice-cold water (1:4) containing 0.03% sodium azide. After centrifugation, 2 mL of the supernatant was condensed to ~200 µL under a nitrogen stream, followed by addition of 1800 µL of acetonitrile and water mixture (80:20), vortexed, centrifuged at 20000 g for 10 min, and the supernatant was collected. The supernatant was divided into two parts; one part was used for HPLC fractionation and radioactivity measurements of the individual fractions, whereas the other part was used to measure the total, unfractionated radioactivity in the sample. 
In Vitro Stability of [ 14 C]Sucrose in Brain Homogenates
Fresh drug-free brain was homogenized (1:9) in citrate-phosphate buffer (10 mM), pH 6.5, and the resulting brain homogenates were spiked with 2500 dpm/mL (0.7 ng/mL) of
sucrose. This concentration was selected to be close to the brain concentrations observed after in vivo administration of 100 µCi of [ 14 C]sucrose in the above fractionation studies. The spiked homogenates were placed in a shaking water bath at 37ᴼC, and samples were taken at zero (baseline) and 3 h, and subjected to the same procedure described above for fractionation studies (i.e., addition of 0.03% sodium azide, centrifugation, 10-fold concentration of the supernatant, and precipitation of proteins with acetonitrile: water). Similarly, the final supernatant was then subjected to both HPLC fractionation, followed by radioactivity measurements of the individual fractions, in addition to counting of the total, unfractionated radioactivity. were made in water and added to an equal volume of pre-saturated 1-octanol in a separating funnel. Subsequently, the contents of the funnel were mixed for 30 min in a rotary machine, and samples (500 µL) were taken from both the water and 1-octanol media for analysis. Additionally, the water part was separated and underwent a second and third partitioning by the addition of equal volumes of fresh 1-octanol, followed by shaking and sampling as described above. For 
Partition Coefficients of [
LC-MS/MS Analysis of [ 13 C]Sucrose
The LC-MS/MS method is described in a recent publication. 24 In brief, samples ( As reported before, 24 the recovery of [ 13 C]sucrose from the brain homogenates at concentrations of 10 (94.0%) and 100 (100%) ng/mL was almost quantitative. However,
additional recovery experiments at a brain homogenate concentration of 3 ng/mL (n = 5) were conducted in the current study to verify the recovery of the marker at concentrations observed in this study. Similar to the previous method, 24 the recovery was determined by comparison of peak areas of brain homogenates and aqueous solutions spiked with [ 13 C]sucrose and subjected to an identical sample preparation method. In agreement with the previous report, 24 the recovery (mean ± SD) at a brain homogenate concentration of 3 ng/mL was 102 ± 4%.
Liquid Scintillation Counting
All radioactive samples (brain, plasma, HPLC fractions) were measured in a Beckman LS6500 liquid scintillation counter with appropriate window settings for 14 C. Quench monitoring (H-number) and automatic quench correction was applied to convert counts per minute (cpm)
into disintegrations per minute per gram tissue (dpm/g) or dpm/mL for brain and plasma samples, respectively.
Pharmacokinetic Analysis
To determine the BBB permeability to both markers in naïve animals, apparent brain uptake clearance (K in ) values were estimated for individual time groups using the following equation:
where !" also estimated from the Patlak plot, 26 which is defined by the following equation:
where !"#$%# 
Statistical Analysis
Statistical analysis of data was performed using Prism software (GraphPad Software, LaJolla, CA). Data with three or more groups were analyzed by one-way ANOVA, followed by Tukey's multiple comparisons. Two-way ANOVA, followed by Bonferroni multiple 
Results
Plasma Kinetics and Brain Disposition Profiles of [ 13 C] and [ 14 C]Sucrose
The plasma concentration-time profiles of Table 1 . As expected, the !"#$%# !!! !"#$ values generally increased with an increase in the sampling time for both markers (p < 0.01, Table 1 ). The plasma concentration-time course (Fig. 1b) and AUC values ( (Fig. 2) . (Fig. 3e) . As demonstrated in Fig. 3 , whereas the dosing solutions (Figs. 3a-c) , the in vitro spiked brain homogenate (Fig. 3d) , and the in vivo plasma sample (Fig. 3e) showed a single peak related to sucrose at ~4.5 min, the chromatograms of the in vivo brain samples contained several prominent peaks, in addition to the peak expected at the sucrose retention time (Figs. 3a-3c ). In fact, most of the total peak areas in the chromatograms of in vivo brain samples could be attributed to the retention times other than that for the sucrose peak (Figs. 3a-3c ). We also measured the total radioactivities of the brain samples in the unfractionated samples to determine the recovery of the radioactivity from the fractionation procedure. The extent of recovery for the three samples was 95.0 ± 7.5%, indicating the chromatograms represent an almost complete recovery of the radioactivity in the brain samples.
Fractionation of Brain and Plasma Samples after In vivo
Stability of [ 13 C]Sucrose in Biological Samples
To determine the possibility of in vivo metabolism of [ 13 C]sucrose, the stability of the marker in various biological media was tested in vitro at 37 o C. To avoid saturation of metabolism, the concentrations of [ 13 C]sucrose were selected to be much lower than the in vivo concentrations achieved after intravenous injection of [ 13 C]sucrose (10 ng/mL ≈ 0.00025 %ID per mL; 4 ng/mL ≈ 0.0001 %ID/mL, and 2 ng/mL ≈ 0.00005 %ID/mL). Figure 4 demonstrates the concentration-time courses of [ 13 C]sucrose in brain homogenate (Fig. 4a ), brain cell co-culture (Fig. 4b) , liver homogenate (Fig. 4c) , and blood (Fig. 4d ). There were no significant changes in the concentrations of the marker in any of the biological samples tested as the slopes of the regression lines for all the biological samples were not significantly (p > 0.05) different from zero (Fig. 4) .
Also shown in Fig. 4 are the chromatograms of brain homogenates before (time zero) and 3 h after incubation of a low concentration (2500 dpm or 0.7 ng per mL) of [ 14 C]sucrose at 37 o C, followed by HPLC fractionation of the samples (Fig. 4e) (Fig. 5a) . However, the K p values of experiments were significantly (p < 0.01 and < 0.001, respectively) lower than that after the first experiment (5.74 x 10 -4 ± 0.40 x 10 -4 ) (Fig. 5b) (Fig. 5c) , which was not used in the studies reported here, were very similar to those of the lot used in the current studies (Fig. 5b ) in terms of both absolute values and pattern after successive partitioning.
Discussion
The search for ideal markers for the in vivo assessment of BBB integrity has been elusive.
However, radiolabeled small molecules, such as sucrose and inulin, are believed to be one of the most appropriate groups of markers for the evaluation of the BBB integrity in pathological conditions. 13 In particular, radiolabeled and 100 fold at 15 min and 2 h, respectively; Fig. 1 and Table 1 ). The rate of back transfer of the marker from the brain to plasma would be negligible during the time when plasma concentrations are much higher than those in the brain. Using a two-compartment model with plasma and brain as separate compartments, Ohno et al. 20 predicted that the brain concentrations of sucrose would reach its maximum around 60 min after an intravenous dose of the tracer, with a very slow rate of decline afterward. 20 However, this model did not include the additional, fastequilibrating space in the brain (represented by V 0 in Equation 2), which was suggested by Patlak et al. 26 In our studies, we observed relatively constant brain concentrations for both (Table 1) . Therefore, our data is in agreement with the presence of the fast-equilibrating space in the brain 26 and/or contamination of our brain samples with residual blood, which both prominently add to the total brain concentrations of the markers at the earlier time points, thus overestimating the brain concentrations and K in values at those single-brain sample points (Table 1) .
Regardless of the experimental design, however, the K in values obtained for the radioactive [ 14 C]sucrose were 6.3-7.6 fold higher than those for [ 13 C]sucrose (Table 1 and Fig.   2 ). This surprising finding prompted us to conduct brain fractionation studies, which revealed that, indeed, most of the radioactivity in the brain after the in vivo administration of [ 14 C]sucrose was attributable to compounds other than the intact sucrose molecule (Fig. 3) . In fact, if one could accurately estimate and use the radioactivity related to the sucrose peak only (Figs. 3a-c Although it is generally believed that sucrose does not enter cells and is not subject to significant metabolism after intravenous administration, the possibility of minor metabolism of the marker in the liver by a very low activity sucrase enzyme has been raised. 47 Additionally, other investigators have shown that α-glucosidase activity, which breaks down starch and disaccharides to glucose, is also present in brain tissue. 48 Therefore, based on the fractionation studies ( Fig. 3) , we initially hypothesized that the intact [ 14 C]sucrose entered into the brain is subsequently metabolized in the brain. However, our in vitro studies with [ 13 C]sucrose in the brain homogenates (Fig. 4a ) and brain cell co-cultures (Fig. 4b) (Fig. 4a) , which showed absence of any noticeable in vitro metabolism of sucrose in the brain homogenate. Furthermore, in vitro spiking of the brain homogenate and subjecting it to the sample preparation method used in the fractionation study did not reveal any additional peaks other than the intact [ A previous study 23 49 and in clinical studies in glioblastoma patients. 50 Given the sensitivity and accuracy of the analytical measurement of 
Conclusions
In conclusion, our data indicate that the use of [ 14 C]sucrose as a marker of BBB permeability might result in a substantial overestimation of the true BBB permeability to sucrose. This is mainly due to the non-specific method of quantitation of the total radioactivity in the brain, which might contain substantial amounts of radioactive compounds other than the intact marker. We suggest that the LC-MS/MS quantitation of the stable isotope ( 13 C) of sucrose is a more accurate alternative to the current widespread use of the radioactive sucrose as a BBB marker. 
